The transthyretin amyloidoses: Advances in therapy

Postgraduate Medical Journal

Volumn 91, Issue 1078, 2015, Pages 439-448

  Dubrey, Simon ^a   Ackermann, Elizabeth ^b   Gillmore, Julian ^c  

^a Hillingdon Hospitals NHS Trust   (United Kingdom)

^b ISIS PHARMACEUTICALS   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ANTISTREPTOLYSIN; ASIALOGLYCOPROTEIN RECEPTOR; BRAIN NATRIURETIC PEPTIDE; DIFLUNISAL; DOXYCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; PATISIRAN; PREALBUMIN; SMALL INTERFERING RNA; TAFAMIDIS; TAUROURSODEOXYCHOLIC ACID; BENZOXAZOLE DERIVATIVE; TAUROCHENODEOXYCHOLIC ACID;

AMYLOIDOSIS; CARPAL TUNNEL SYNDROME; ECHOCARDIOGRAPHY; FAMILIAL AMYLOID POLYNEUROPATHY; FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; GENE MUTATION; GENE SILENCING; HEART FAILURE; HEART MUSCLE BIOPSY; HEART VENTRICLE HYPERTROPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCINTIGRAPHY; AMYLOID NEUROPATHIES, FAMILIAL; METABOLISM; MOLECULARLY TARGETED THERAPY; MORTALITY; PROCEDURES; PROGNOSIS; TRENDS;

AMYLOID NEUROPATHIES, FAMILIAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZOXAZOLES; DOXYCYCLINE; ECHOCARDIOGRAPHY; HUMANS; LIVER TRANSPLANTATION; MOLECULAR TARGETED THERAPY; PREALBUMIN; PROGNOSIS; RNA, SMALL INTERFERING; TAUROCHENODEOXYCHOLIC ACID;

EID: 84940450929     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/postgradmedj-2014-133224     Document Type: Review

References (123)

1. Sousa MM, Cardoso I, Fernandes R, et al. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of non-fibrillar aggregates. Am JPathol 2001; 159: 1993-2000.
2. Sörgjerd K, Klingstedt T, Lindgren M, et al. Prefibrillar transthyretin oligomers and cold stored native tetrameric transthyretin are cytotoxic in cell culture. Biochem Biophys Res Commun 2008; 377: 1072-8.
3. Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation 2012; 126: 1286-300.
4. Perlini S, Obici L, dell'Acqua R, et al. Differences in NT-proBNP release in patients with cardiac m-ATTR depend on the specific transthyretin mutation. XIVth International Symposium on Amyloidosis; OP83. Indianapolis, USA, 2014: 100-1. http://www. amyloidosis. nl/indpls/XIVth%20International%20Symposium%20on% 20Amyloidosis%20Book. pdf (accessed 20 Dec 2014).
5. Swiecicki PL, Zhen DB, Mauerman ML, et al. Hereditary amyloidosis: a single centre experience with 284 patients. XIVth International Symposium on Amyloidosis; OP53. Indianapolis, USA, 2014: 72. http://www. amyloidosis. nl/indpls/XIVth%20International%20Symposium%20on%20Amyloidosis%20Book. pdf (accessed 20 Dec 2014).
6. Rowczenio D, Wechalekar A. Mutations in hereditary amyloidosis. 2010. http://amyloidosismutations. com/mut-attr. php (accessed 05/10/2014).
7. Kristen AV, Damy T, Mundayat R, et al, on behalf of the THAOS investigators. Cardiac findings in TTR amyloidosis: a report from the Transthyretin Amyloid Outcome Survey (THAOS). XIVth International Symposium on Amyloidosis; PC27. Indianapolis, USA, 2014: 236-7. http://www. amyloidosis. nl/indpls/XIVth% 20International%20Symposium%20on%20Amyloidosis%20Book. pdf (accessed 20 Dec 2014).
8. Quarta CC, Falk RH, Solomon SD, et al. The prevalence of cardiac amyloidosis in familial amyloidotic polyneuropathy with predominant neuropathy: The Diflunisal Trial. XIVth International Symposium on Amyloidosis; OP69. Indianapolis, USA, 2014: 88. http://www. amyloidosis. nl/indpls/XIVth%20International%20Symposium %20on%20Amyloidosis%20Book. pdf (accessed 16 Feb 2015).
9. Saraiva MJM. Database on transthyretin mutations. 2001. http://www. ibmc. up. pt/mjsaraiva/ttrmut. html (accessed 18 Feb 2014).
10. Hattori T, Takei Y, Koyama J, et al. Clinical and pathological studies of cardiac amyloidosis in transthyretin type familial amyloid polyneuropathy. Amyloid 2003; 10: 229-39.
11. Hornsten R, Pennlert J, Wiklund U, et al. Heart complications in familial transthyretin amyloidosis: impact of age and gender. Amyloid 2010; 17: 63-8.
12. Lane T, Bangova A, Fontana M, et al. TRANSCEND-(TRanscend Amyloidosis: Neuropathy, Senility, Cardiomyopathy: Evaluation, Natural history and Diagnosis)-a comprehensive observational study of transthyretin amyloidosis. XIVth International Symposium on Amyloidosis; PC28. Indianapolis, USA, 2014: 238. http://www. amyloidosis. nl/indpls/XIVth%20International%20Symposium%20on% 20Amyloidosis%20Book. pdf (accessed 20 Dec 2014).
13. Mincheva Z, Cauquil C, Adam C, et al. Teachings from the French database of transthyretin familial amyloid polyneuropathy (TTR-FAP): sporadic, genetic, and phenotypic heterogeneity in late onset cases. XIVth International Symposium on Amyloidosis; PC31. Indianapolis, USA, 2014: 241-2. http://www. amyloidosis. nl/indpls/XIVth%20International%20Symposium%20on%20Amyloidosis%20Book. pdf (accessed 20 Dec 2014).
14. Westermark P, Bergstrom J, Solomon A, et al. Transthyretin-derived senile systemic amyloidosis: clinicopathologic and structural considerations. Amyloid 2003; 10: 48-54.
15. Ng B, Connors LH, Davidoff R, et al. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Int Med 2005; 165: 1425-9.
16. Tojo K, Tsuchiya-Suzuki A, Sekijima Y, et al. Upper limb neuropathy such as carpal tunnel syndrome as an initial manifestation of ATTR Val30Met familial amyloid polyneuropathy. Amyloid 2010; 17: 32-5.
17. Pitkanen P, Westermark P, Cornwell GG. Senile systemic amyloidosis. Am J Pathol 1984; 117: 391-9.
18. Sueyoshi T, Ueda M, Sei A, et al. Spinal multifocal amyloidosis derived from wild-type transthyretin. Amyloid 2011; 18: 165-8.
19. Ueda M, Horibata Y, Shono M, et al. Clinicopathological features of senile systemic amloidosis: an ante-and post-mortem study. Mod Pathol 2011; 24: 1533-44.
20. Pinney JH, Whelan CJ, Petrie A, et al. Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc 2013; 2: e000098.
21. Cowan AJ, Skinner M, Seldin DC, et al. Amyloidosis of the gastrointestinal tract: a 13 year, single-center referral experience. Haematologica 2013; 98: 141-6.
22. Sachchithanantham S, Gillmore JD, Gilbertson J, et al. Painless haematuria is a manifestation of senile systemic amyloidosis. XIVth International Symposium on Amyloidosis; PC45. Indianapolis, USA, 2014: 256. http://www. amyloidosis. nl/indpls/XIVth%20International%20Symposium%20on%20Amyloidosis%20Book. pdf (accessed 16 Feb 2015).
23. Cornwell GG III, Murdoch WL, Kyle RA, et al. Frequency and distribution of senile cardiovascular amyloid. A clinicopathological correlation. Am J Med 1983; 75: 618-23.
24. Rapezzi C, Quarta CC, Guidalotti PL, et al. Role of (99m) Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin related cardiac amyloidosis. J Am Coll Cardiol 2011; 4: 659-70.
25. Wechalekar AD, Gillmore JD, Gibbs SDJ, et al. 25 years of amyloidosis in the UK-single centre experience of 5100 patients. XIIIth International Symposium on Amyloidosis; PC 28. Groningen, the Netherlands. 6-10 May 2012 http://wencke4. housing. rug. nl/documenten/medici/Internationale_Conferenties/SY_Amyloidosis% 202012/documents/ISAabstractbook2012. pdf (accessed 16 Feb 2014).
26. Wilczek HE, Larsson M, Larsson BG, on behalf of reporting members of the FAPWTR. Long-term data from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR). Amyloid 2011; 18193-5.
27. Coelho T, Ericzon B-G, Falk R, et al. A physicians' guide to transthyretin amyloidoisis. Amyloidosis Foundation, 2008. http://www. amyloidosis. org/pdf/TTR% 2008. pdf (accessed 19 Feb 2015).
28. Connors LH, Prokaeva T, Lim A, et al. Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am Heart J 2009; 158: 607-14.
29. Jacobson DR, Pastore RD, Yaghoubian R, et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 1997; 336: 466-73.
30. Connors LH, Lim A, Prokaeva T, et al. Tabulation of human transthyretin (TTR) variants. Amyloid 2003; 10: 160-84.
31. Quarta CC, Buxbaum JN, Shah AM, et al. The amyloidogenic V122I transthyretin variant in elderly Black Americans. New Engl J Med 2015; 372: 21-9.
32. Buxbaum J, Jacobson DR, Tagoe C, et al. Transthyretin V122I in African Americans with congestive heart failure. J Am Coll Cardiol 2006; 47: 1724-5.
33. Dungu JN, Anderson LJ, Whelan CJ, et al. Cardiac transthyretin amyloidosis. Heart 2012; 98: 1546-54.
34. Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol 2005; 62: 1057-62.
35. Hund E. Familial amyloid polyneuropathy: current and emerging treatment options for transthyretin-mediated amyloidosis. Appl Clin Genet 2012; 5: 37-41.
36. Givens RC, Russo C, Green P, et al. Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic center. Aging Health 2013; 9: 229-35.
37. Ruberg FL, Maurer MS, Judge DP, et al. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis cardiac Study (TRACS). Am Heart J 2012; 164: 222-8.
38. Connors LH, Sam F, Sun FG, et al. A five year prospective longitudinal study of patients with senile systemic amyloidosis. XIVth International Symposium on Amyloidosis; PC12. Indianapolis, USA, 2014: 221-2. http://www. amyloidosis. nl/indpls/XIVth%20International%20Symposium%20on%20Amyloidosis%20Book. pdf (accessed 20 Dec 2014).
39. Grogan M, Zeldenrust SR, Maleszewski JJ, et al. Clinical characteristics and survival in 272 patients with senile systemic amyloidosis and histologically proven cardiac involvement. XIVth International Symposium on Amyloidosis; PC21. Indianapolis, USA, 2014: 230-1. http://www. amyloidosis. nl/indpls/XIVth% 20International%20Symposium%20on%20Amyloidosis%20Book. pdf (accessed 20 Dec 2014).
40. Patel KS, Sayed R, Sachchithanantham S, et al. A retrospective comparison of senile systemic amyloidosis and V122I-associated ATTR amyloidosis. XIVth International Symposium on Amyloidosis; PC37. Indianapolis, USA, 2014: 246-7. http://www. amyloidosis. nl/indpls/XIVth% 20International%20Symposium%20on%20Amyloidosis%20Book. pdf (accessed 20 Dec 2014).
41. Anesi E, Palladini G, Perfetti V, et al. Therapeutic advances demand accurate typing of amyloid deposits. Am J Med 2001; 111: 243-4.
42. Lachmann HJ, Booth DR, Booth SE, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. New Eng J Med 2002; 346: 1786-91.
43. Dungu J, Sattianayagam PT, Whelan CJ, et al. The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro-Caribbean patients. Am Heart J 2012; 164: 72-9.
44. Perugini E, Rapezzi C, Piva T, et al. Non-invasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance. Heart 2006; 92: 343-9.
45. Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3, 3-diphosphon-1, 2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005; 46: 107-1084.
46. Minutoli F, DiBella G, Mazzeo A, et al. Comparison Between 99mTc-Diphosphonate imaging and MRI with late gadolinium enhancement in evaluating cardiac involvement in patients with transthyretin familial amyloid polyneuropathy. Am J Roent 2013; 200: w256-65.
47. Adams D, Samuel D, Siama M. Treatment of familial amyloid polyneuropathy. Presse Med 2012; 411): 793-806.
48. Kristen AV, Dengler TJ, Hegenbart U, et al. Prophylactic implantation of cardioverter-defibrillators in patients with severe cardiac amyloidosis and high risk of sudden cardiac death. Heart Rhythm 2008; 5: 235-40.
49. Lin G, Dispenzieri A, Grogan M, et al. Outcomes of implantable defibrillators in patients with cardiac amyloidosis. Amyloid 2010; 17: 166a.
50. Dubrey SW, Burke MM, Hawkins PN, et al. Cardiac transplantation for amyloid heart disease-the United Kingdom experience. J Heart Lung Transplant 2004; 23: 1142-53.
51. Niehaus E, Gilstrap L, Maurer M, et al. Outcomes from an international registry of cardiac transplantation for light chain (AL) and transthyretin amyloidosis. XIVth International Symposium on Amyloidosis; OP78. Indianapolis, USA, 2014: 96. http://www. amyloidosis. nl/indpls/XIVth%20International%20Symposium%20on% 20Amyloidosis%20Book. pdf (accessed 20 Dec 2014).
52. Dubrey SW, Comenzo RL. Amyloid heart disease: current and future therapies. QJM 2012; 105: 617-31.
53. Sekijima Y. Recent progress in the understanding and treatment of transthyretin amyloidosis. Clin Pharm Ther 2014; 39: 225-33.
54. Holmgren G, Ericzon BG, Groth CG, et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 1993; 341: 1113-16.
55. Herlenius G, Wilczek HE, Larsson M, et al. Familial Amyloidotic Polyneuropathy World Transplant Registry. Ten years of International experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic World Transplant Registry. Transplantation 2004; 77: 64-71.
56. Pilato E, Dell'Amore A, Botta L, et al. Combined heart and liver transplantation for amyloidotic neuropathy. Eur J Cardiothorac Surg 2007; 32: 180-2.
57. Barreiros AP, Post F, Hoppe-Lotichius M, et al. Liver transplantation and combined liver-heart transplantation in patients with familial amyloid polyneuropathy: a single-center experience. Liver Transpl 2010; 16: 314-23.
58. The Familial Amyloidotic Polyneuropathy World Transplant Registry and The Domino Liver Transplant Registry. http://www. fapwtr. org/ram1. htm (accessed 30 Sep 2014).
59. Adams D, Samuel D, Goulon-Goeau C, et al. The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. Brain 2000; 123: 1495-504.
60. Dubrey S, Davidoff R, Skinner M, et al. Progression of ventricular wall thickening following liver transplantation for familial amyloidosis. Transplantation 1997; 64: 74-80.
61. Pomfret EA, Lewis WD, Jenkins RL, et al. Effect of orthotopic liver transplantation on the progression of familial amyloidotic polyneuropathy. Transplantation 1998; 65: 918-25.
62. Stangou AJ, Hawkins PN, Heaton ND, et al. Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis. Transplantation 1998; 66: 229-33.
63. Garcia-Herola A, Prieto M, Pascual S, et al. Progression of cardiomyopathy and neuropathy after liver transplantation in a patient with familial amyloidotic polyneuropathy caused by tyrosine-77 transthyretin variant. Liver Transpl Surg 1999; 5: 246-8.
64. Yazaki M, Tokuda T, Nakamura A, et al. Cardiac amyloid in patients with familial amyloid polyneuropathy consists of abundant wild-type transthyretin. Biochem Biophys Res Comms 2000; 274: 702-6.
65. Yazaki M, Mitsuhashi S, Tokuda T, et al. Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients. Am J Transplant 2007; 7: 235-42.
66. Liepnieks JJ, Benson MD. Progression of cardiac amyloid deposition in hereditary transthyretin amyloidosis patients after liver transplantation. Amyloid 2007; 14: 277-82.
67. Yamashita T, Ando Y, Okamoto S, et al. Effect of liver transplantation on the survival of patients with ordinary onset FAP in Japan. Amyloid 2011; 18(Supp 1): 185-6.
68. Tsuchiya A, Yazaki M, Kametani F, et al. Marked regression of abdominal fat amyloid in patients with familial amyloid polyneuropathy during long term follow-up after liver transplantation. Liver Transpl 2008; 14: 563-70.
69. Stangou AJ, Hawkins PN. Liver transplantation in transthyretin-related familial amyloid polyneuropathy. Curr Opin Neurol 2004; 17: 615-20.
70. Okamoto S, Wixner J, Obayashi K, et al. Liver transplantation for familial amyloidotic polyneuropathy: impact on Swedish patients survival. Liver Transpl 2009; 15: 1229-35.
71. Ericzon B-G, Wilczek HE, Larsson M, et al. Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative. Transplantation 2015 doi: 10. 1097/TP. 0000000000000574 http://journals. lww. com/transplantjournal/Abstract/onlinefirst/Liver_Transplantation_for_Hereditary_Transthyretin. 97902. aspx.
72. Stangou AJ, Heaton ND, Hawkins PN. Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation. N Engl J Med 2005; 352: 2356.
73. Llado L, Baliellas C, Cassasnovas C, et al. Risk of transmission of systemic transthyretin amyloidosis after domino liver transplantation. Liver Transpl 2010; 16: 1386-92.
74. Suhr OB, Herlenius G, Friman S, et al. Liver transplantation for hereditary transthyretin amyloidosis. Liver Transpl 2000; 6: 263-76.
75. Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010; 50: 529-93.
76. Benson MD, Kluve-Beckerman B, Zeldenrust SR, et al. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve 2006; 33: 609-18.
77. Kurosawa T, Igarashi S, Nishizawa M, et al. Selective silencing of mutant transthyretin allele by small interfering RNAs. Biochem Biophys Res Commun 2005; 337: 1012-18.
78. Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 2013; 369: 819-29.
79. Ackermann EJ, Guo S, Booten S, et al. Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid 2012; 19: 43-4.
80. Schwarzman AL, Gregori L, Vitek MP, et al. Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc Natl Acad Sci USA 1994; 91: 8368-72.
81. Ando Y, Suhr OB. Autonomic dysfunction in familial amyloidotic polyneuropathy (FAP). Amyloid 1998; 5: 288-300.
82. Butler JS, Chan A, Costelh S, et al. Preclinical evaluation of RNAi therapeutics for the treatment of ATTR: an update. XIVth International Symposium on Amyloidosis; PC9. Indianapolis, USA, 2014: 219-20. http://www. amyloidosis. nl/indpls/XIVth% 20International%20Symposium%20on%20Amyloidosis%20Book. pdf (accessed 20 Dec 2014).
83. Suhr O, Adams D, Coelho T, et al. Further analysis of phase II trial of patisiran, a novel RNAi therapeutic for the treatment of familial amylodotic polyneuropathy. XIVth International Symposium on Amyloidosis; OP72. Indianapolis, USA, 2014: 91-2. http://www. amyloidosis. nl/indpls/XIVth%20International% 20Symposium%20on%20Amyloidosis%20Book. pdf (accessed 20 Dec 2014).
84. Gillmore JD, Falk RH, Maurer MS, et al. A phase 2 multi-center, open label trial to evaluate the safety, pharmacokinetics and exploratory clinical activity of revusiran (ALN-TTRsc), an RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis. http://www. alynam. com/web/assets/Revusiran-ACC-15Mar2015. pdf (accessed 20 Apr 2015).
85. Hammarstrom P, Wiseman RL, Powers ET, et al. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 2003; 299: 713-16.
86. Arsequell G, Planas A. Methods to evaluate the inhibition of TTR fibrillogenesis induced by small ligands. Current Medicinal Chemistry 2012; 19: 1-13.
87. Coelho T, Maia L, Martins da Solva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized controlled trial. Neurology 2012; 79: 785-92.
88. Coelho T, Maia LF, da Silva AM, et al. Long term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol 2013; 260: 2802-14.
89. Coelho T, Silva AM, Valdrez K, et al. Familial amyloid polyneuropathy treatment with tafamidis-evaluation of one year treatment at Porto, Portugal. XIVth International Symposium on Amyloidosis; OP67. Indianapolis, USA, 2014: 86-7. http://www. amyloidosis. nl/indpls/XIVth%20International%20Symposium%20on% 20Amyloidosis%20Book. pdf (accessed 20 Dec 2014).
90. Falk RH, Maurer MS, Fedson SE, et al. Tafamidis stabilizes transthyretin and improves clinical outcomes in transthyretin amyloid cardiomyopathy. J Cardiac Fail 2011; 17: S56.
91. Merlini G, Coelho T, Falk RH, et al. Transthyretin stabilisation, efficacy and safety of tafamidis for the treatment of transthyretin amyloidosis. XIIIth International Symposium on Amyloidosis; PC 49. Groningen, Netherlands. 6-10 May 2012: 204. http://wencke4. housing. rug. nl/documenten/medici/Internationale_Conferenties/SY_Amyloidosis%202012/documents/ISAabstractbook2012. pdf (accessed 16 Feb 2014).
92. Maurer MS, Judge DP, Rosas GR, et al. Interim analysis of long term, open-label tafamidis treatment in transthyretin amyloid cardiomyopathy after up to 5 years of treatment. XIVth International Symposium on Amyloidosis; OP66. Indianapolis, USA, 2014: 85-6. http://www. amyloidosis. nl/indpls/XIVth%20International% 20Symposium%20on%20Amyloidosis%20Book. pdf (accessed 20 Dec 2014).
93. Merlini G, Waddington-Cruz M, Stewart M, et al. Survival in patients with transthyretin familial amyloid polyneuropathy receiving tafamidis treatment. XIVth International Symposium on Amyloidosis; OP65. Indianapolis, USA, 2014: 84. http://www. amyloidosis. nl/indpls/XIVth%20International%20Symposium%20on% 20Amyloidosis%20Book. pdf (accessed 20 Dec 2014).
94. Sekijima Y, Dendle MA, Kelly JW. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid 2006; 13: 236-49.
95. Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 2013; 310: 2658-67.
96. Sekijima Y, Tojo K, Morita H, et al. Safety and efficacy of long-term diflunisal administration in familial amyloid polyneuropathy-Summary of ten years therapeutic experience. XIVth International Symposium on Amyloidosis; OP70. Indianapolis, USA, 2014: 89-90. http://www. amyloidosis. nl/indpls/XIVth% 20International%20Symposium%20on%20Amyloidosis%20Book. pdf (accessed 20 Dec 2014).
97. Sant'Anna RO, Braga CA, Polikarpov I, et al. Inhibition of human transthyretin aggregation by non-steroidal anti-inflammatory compounds: a structural and thermodynamic analysis. Int J Mol Sci 2013; 149: 5284-311.
98. Cardoso I, Saraiva MJ. Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model. FASEB J 2006; 20: 234-9.
99. Obici L, Cortese A, Lozza A, et al. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid 2012; 19: 34-6.
100. Obici L, Cortese A, Lozza A, et al. A phase II study of doxycycline plus tauroursodeoxycholic acid in transthyretin amyloidois. XIVth International Symposium on Amyloidosis; OP67. Indianapolis, USA, 2014: 86-7. http://www. amyloidosis. nl/indpls/XIVth%20International%20Symposium%20on% 20Amyloidosis%20Book. pdf (accessed 20 Dec 2014).
101. Merlini G, Ascari E, Amboldi N, et al. Interaction of the anthracycline 40-iodo-40deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. Proc Nat Acad Sci USA 1995; 92: 2959-63.
102. Sebastiao MP, Merlini G, Saraiva MJ, et al. The molecular interaction of 40-iodo-40deoxyrubicin with Leu55Pro transthyretin 'amyloid-like' oligomer leading to disaggregation. Biochem J 2000; 351: 273-9.
103. Palha JM, Ballinari D, Amboldi N, et al. 40-iodo-40deoxydoxorubicin disrupts the fibrillar structure of transthyretin amyloid. Am J Pathol 2000; 156: 1919-25.
104. Stefani M, Rigacci S. Protein folding and aggregation into amyloid: the interference by natural phenolic compounds. Int J Mol Sci 2013; 14: 12411-57.
105. Kristen AV, Buss S, Mereles D, et al. Green tea halts progression of cardiac transthyretin amyloidosis-a pilot study. XIIIth International Symposium on Amyloidosis; PC 43. 6-10 May 2012: 200-1. Groningen, the Netherlands. http://wencke4. housing. rug. nl/documenten/medici/Internationale_Conferenties/SY_Amyloidosis%202012/documents/ISAabstractbook2012. pdf (accessed 16 Feb 2014).
106. Ferreira N, Santos SAO, Domingues MRM, et al. Dietary curcumin conteracts extracellular transthyretin deposition: insights on the mechanism of amyloid inhibition. Biochem Biophys Acta 2013; 1832: 39-45.
107. Green NS, Foss TR, Kelly JW. Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis. Proc Nat Acad Sci USA 2005; 102: 14545-50.
108. Ferreira N, Saraiva MJ, Almeida MR. Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation. FEBS Lett 2011; 585: 2424-30.
109. Ferreira N, Saraiva MJ, Almeida MR. Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: in vivo evidence from FAP mice models. PLoS ONE 2012; 7: e29933.
110. Hunstein W. Epigallocathechin-3-gallate in AL amyloidosis: a new therapeutic option. Blood 2007; 110: 2216.
111. Bieschke J, Russ J, Friedrich RP, et al. EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. Proc Natl Acad Sci USA 2010; 107: 7710-15.
112. Nakagawa K, Sheikh SI, Snuderl M, et al. A new Thr49Pro transthyretin gene mutation associated with leptomeningeal amyloidosis. J Neurol Sci 2008; 272: 186-90.
113. Macedo B, Magalhães J, Batista AR, et al. Carvedilol treatment reduces transthyretin deposition in a familial amyloidotic polyneuropathy mouse model. Pharmacol Res 2010; 62: 514-22.
114. Bourgault S, Choi S, Buxbaum JN, et al. Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratol analogs. Biochem Biophys Res Commun 2010; 410: 707-13.
115. Nuvolone M, Obici L, Merlini M. Transthyretin-associated familial amyloid polyneuropathy-current and emerging therapies. Touch briefings. US Neurol 2012; 8: 24-32.
116. Terazaki H, Ando Y, Fernandes R, et al. Immunization in familial amyloidotic polyneuropathy: counteracting deposition by immunization with a Y78F TTR mutant. Lab Invest 2006; 86: 23-31.
117. Saraiva MJM. Transthyretin mutations in hyperthyroxinemia and amyloid disease. Hum Mutat 2010; 17: 493-503.
118. Coelho T, Chorão R, Sousa A, et al. Compound heterozygotes of transthyretin Met30 and transthyretin Met119 are protected from the devastating effects of familial amyloid polyneuropathy. Neuromuscul Disord 1996; 6: S20.
119. Hammarström P, Schneider F, Kelly JW. Trans-suppression of misfolding in an amyloid disease. Science 2001; 293: 2459-62.
120. Batista AR, Gianni D, Ventosa M, et al. Gene therapy approach to FAP: in vivo influence of T119M in TTR deposition in a transgenic V30M mouse model. Gene Ther 2014; 21: 1041-50.
121. Pepys MB, Herbert J, Hutchinson WL, et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002; 417: 254-9.
122. Bodin K, Ellmerich S, Kahan MC, et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 2010; 468: 93-7.
123. Gillmore JD, Tennent GA, Hutchinson WL, et al. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. Br J Haematol 2010; 148: 760-7.